Short-course sublingual immunotherapy by mucoadhesive patch and tolerogenic particle enhanced allergen presentation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F21%3AN0000117" target="_blank" >RIV/00027162:_____/21:N0000117 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/21:10427891 RIV/46747885:24620/21:00008627 RIV/61989592:15110/21:73607582

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1111/cea.13862" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/cea.13862</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/cea.13862" target="_blank" >10.1111/cea.13862</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Short-course sublingual immunotherapy by mucoadhesive patch and tolerogenic particle enhanced allergen presentation

Popis výsledku v původním jazyce

Allergen immunotherapy (AIT) is the only currently available medical intervention that can limit the natural course of allergic rhinitis and lead to long-term disease modification.1 Although the subcutaneous route of immunization has previously been considered a reference for AIT, it is now well established that sublingual immunotherapy (SLIT) is an effective and safer alternative and has recently been explored in food allergy with promising results.2 The excellent safety profile of SLIT can be explained by the fact that oral tissues constitute an immune-privileged gateway containing few proinflammatory cells and exhibiting an allergen-tolerogenic phenotype prone to orient immune responses towards a Th1/Treg-cell profile.

Název v anglickém jazyce

Short-course sublingual immunotherapy by mucoadhesive patch and tolerogenic particle enhanced allergen presentation

Popis výsledku anglicky

Allergen immunotherapy (AIT) is the only currently available medical intervention that can limit the natural course of allergic rhinitis and lead to long-term disease modification.1 Although the subcutaneous route of immunization has previously been considered a reference for AIT, it is now well established that sublingual immunotherapy (SLIT) is an effective and safer alternative and has recently been explored in food allergy with promising results.2 The excellent safety profile of SLIT can be explained by the fact that oral tissues constitute an immune-privileged gateway containing few proinflammatory cells and exhibiting an allergen-tolerogenic phenotype prone to orient immune responses towards a Th1/Treg-cell profile.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30225 - Allergy

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical and Experimental Allergy

ISSN

0954-7894

e-ISSN

1365-2222

Svazek periodika

51

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

853-857

Kód UT WoS článku

000627556200001

EID výsledku v databázi Scopus

2-s2.0-85102296247